A Critical Pathway for Implantable Cardioverter-Defibrillators in Patients With Ischemic Cardiomyopathy (CAPTURE)
Status
Conditions
Treatments
Details and patient eligibility
About
The purpose of this study is to develop and implement a critical pathway to identify patients with ischemic cardiomyopathy who are candidates for an implantable cardioverter-defibrillator (ICD). This study will also determine whether the use of the critical pathway for ICDs is associated with a change in the ICD referral and implantation rate.
Full description
Despite improvements in both medical management and revascularization strategies, sudden death is still a significant complication in patients with ischemic cardiomyopathy. There is strong evidence to support the role of ICDs for the primary prevention of sudden death in this population. However, in Canada and the United States, ICDs are underutilized.
Critical pathways are algorithms that improve health care delivery and clinical outcomes while reducing practice variability. The use of a critical pathway to assess a patient's eligibility for an ICD may increase the appropriate use of this evidence-based technology.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
- acute ST segment elevation myocardial infarction (STEMI)
- candidate for percutaneous revascularization
- permanent residents of British Columbia, Canada
Exclusion criteria
- patients with heart disease or a comorbid illness who have a documented life expectancy of less than 1 year
Trial design
Primary purpose
Allocation
Interventional model
Masking
600 participants in 2 patient groups
Trial contacts and locations
Loading...
Central trial contact
S Cowan, MD, MSc
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal